Medicinski arhiv 2012-01-01

Betahistine or Cinnarizine for treatment of Meniere's disease.

Jasminka Djelilovic-Vranic, Azra Alajbegovic, Merita Tiric-Campara, Aida Volic, Zehra Sarajlic, Eldina Osmanagic, Ljubica Todorovic, Omer Beslagic

Index: Med. Arh. 66(6) , 396-8, (2012)

Full Text: HTML

Abstract

Meniere's disease is a condition with sudden attacks of vertigo with nausea and vomiting accompanied by loss of hearing and buzzing sensation in the ears, most commonly unilateral. The exact cause of the disease is unknown. Betahistine is the analogue of histamine with weaker agonistic effect on histamine H1 receptors and stronger effect on histamine H3 receptors, while Cinnarizine has more effective effect on H1 receptors.The aim is to determine which drug is more effective in the treatment of Meniere's disease Betahistine or Cinnarizine.This study evaluates the effectiveness of Betahistine in 37 patients with the Meniere's syndrome accompanied by classic triad of symptoms treated in hospital conditions and Cinnarizine effect in 36 patients with a less severe clinical picture, which were treated as outpatients. To all patients were conducted laboratory tests, brain CAT (to exclude possible expansive process, MS or stroke) and TCD in order to eliminate any possible circulatory disturbances in VB basin. Group with classic Meniere's syndrome was treated at a dose of Betahistine of 3 x 16 mg and followed 8 weeks, while the second group was treated with Cinnarizine at a dose of 2 x 75 mg and also followed for 8 weeks.Already after one month of therapy was noticed better effect in case of Betahistine in terms of symptoms reduction compared to the Cinnarizine effect.


Related Compounds

Related Articles:

Iron oxide induced enhancement of mucoadhesive potential of Eudragit RLPO: formulation, evaluation and optimization of mucoadhesive drug delivery system.

2013-09-01

[Expert Opin. Drug Deliv. 10(9) , 1179-91, (2013)]

A combination turbidity and supernatant microplate assay to rank-order the supersaturation limits of early drug candidates.

2014-10-01

[J. Pharm. Sci. 103(10) , 3022-32, (2014)]

Factors influencing crystal growth rates from undercooled liquids of pharmaceutical compounds.

2014-08-21

[J. Phys. Chem. B 118(33) , 9974-82, (2014)]

An in vivo antilymphatic screen in zebrafish identifies novel inhibitors of mammalian lymphangiogenesis and lymphatic-mediated metastasis.

2014-10-01

[Mol. Cancer Ther. 13(10) , 2450-62, (2014)]

Circumvention of inherent or acquired cytotoxic drug resistance in vitro using combinations of modulating agents.

2013-10-01

[Anticancer Res. 33(10) , 4381-7, (2013)]

More Articles...